366 results on '"PONTIERI, FRANCESCO E."'
Search Results
2. The impact of cerebral vasomotor reactivity on cerebrovascular diseases and cognitive impairment
3. The Story behind the Mask: A Narrative Review on Hypomimia in Parkinson’s Disease
4. The tolerability, safety and efficacy of safinamide in elderly Parkinson’s disease patients: a retrospective study
5. Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson’s disease
6. Safinamide improves executive functions in fluctuating Parkinson’s disease patients: an exploratory study
7. Four Days Are Enough to Provide a Reliable Daily Step Count in Mild to Moderate Parkinson’s Disease through a Commercial Smartwatch
8. Correction to: The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients
9. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients
10. Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings.
11. Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease
12. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
13. Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson’s Disease: Beyond the Primary Mechanism of Action
14. Levodopa/carbidopa intestinal gel via percutaneous endoscopic transgastric jejunostomy in advanced Parkinson's disease: hitting two birds with one stone?
15. Orthostatic hypotension acutely impairs executive functions in Parkinson’s disease
16. Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study
17. Age at Onset Influences Progression of Motor and Non-Motor Symptoms during the Early Stage of Parkinson’s Disease: A Monocentric Retrospective Study
18. Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
19. Correction to: Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study
20. Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy
21. Metabolic Mapping of the Effects of Psychomotor Stimulants
22. Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson׳s disease
23. Step-Counting Accuracy of a Commercial Smartwatch in Mild-to-Moderate PD Patients and Effect of Spatiotemporal Gait Parameters, Laterality of Symptoms, Pharmacological State, and Clinical Variables
24. Cognitive dual-task cost depends on the complexity of the cognitive task, but not on age and disease
25. Rasagiline for dysexecutive symptoms during wearing-off in Parkinson’s disease: a pilot study
26. Supine hypertension in Parkinson’s disease and multiple system atrophy
27. Feasibility, Safety, and Effectiveness of Telerehabilitation in Mild-to-Moderate Parkinson's Disease
28. Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel
29. Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common $\mu_1$ Opioid Receptor Mechanism
30. Step-Counting Accuracy of a Commercial Smartwatch in Mild-to-Moderate PD Patients and Effect of Spatiotemporal Gait Parameters, Laterality of Symptoms, Pharmacological State, and Clinical Variables.
31. Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease
32. Alexithymia Is a Non-Motor Symptom of Parkinson Disease
33. Detecting nocturnal hypertension in Parkinson’s disease and multiple system atrophy: proposal of a decision-support algorithm
34. The early course of affective and cognitive symptoms in de novo patients with Parkinson’s disease
35. DUOGLOBE : One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
36. Validation of the Canadian Occupational Performance Measure in Italian Parkinson’s Disease Clients
37. Switch from rasagiline to safinamide in fluctuating Parkinson’s disease patients: a retrospective, pilot study
38. Immune System and Neuroinflammation in Idiopathic Parkinson’s Disease: Association Analysis of Genetic Variants and miRNAs Interactions
39. Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders
40. Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson’s disease
41. The recognition of facial emotion expressions in Parkinson's disease
42. Rotigotine for anxiety during wearing-off in Parkinson’s disease with dementia
43. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study
44. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy
45. Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease
46. Botulinum toxin type A for Holmes tremor secondary to thalamic hemorrhage
47. Cerebellar GABA Levels and Cognitive Interference in Parkinson’s disease and Healthy Comparators
48. Safinamide improves executive functions in fluctuating Parkinson’s disease patients: an exploratory study
49. Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE
50. HEDONIC TONE AND ITS MOOD AND COGNITIVE CORRELATES IN PARKINSONʼS DISEASE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.